Institutional Biosafety Committee

The CU Anschutz | CU Denver Institutional Biosafety Committee provides review and approval for a wide range of research activities on CU campuses. Protocols are reviewed and overseen for compliance with the National Institute of Health (NIH) Guidelines and Federal Select Agents Regulations, as well as state & institutional requirements for research on campus.

The IBC meets monthly to review biosafety applications.

For researchers using human samples, the Biosafety Office has provided updated guidance for researchers with regards to COVID-19 safety.

Please direct all questions regarding IBC requirements and review processes to [email protected].

Review and approval of research on campus involving any of the items indicated below, alone or in combination:

Recombinant DNA materials (including recombinant proteins, vectors, etc)
Transgenic animals or plants
Infectious materials
Biohazardous materials
Select Agent toxins
Human materials (cells, fluids, tissues, etc)
Human Gene Transfer or Live Vaccine clinical trials
Clinical trials involving institutionally created investigational compounds
Incident Reporting and Investigations for incidents involving infectious or recombinant DNA materials
Institutional Biosafety Committee Policy and Procedures

All new and renewal IBC applications must be entered in Cayuse- word files will not be accepted. For amendment instructions, please contact the IBC Coordinator ([email protected]) for instructions.

Cayuse can be accessed here. Before attempting to submit an IBC protocol, please review this document regarding Accessing and Starting an IBC Protocol within Cayuse

Please review the CU Denver IBC Compliance Note

If working with Select Agent Toxins, a new letter of support from your department chair/head is required for new or de novo submissions. Here is a a Support Letter Template or you may utilize your department's preferred format.

The IBC reviews human clinical trials involving Human Gene Transfer, Live Vaccine, and some institutionally-mandated investigational compounds. The IBC also reviews manufacturing activities on CU-affiliated institutions that pertain to biological substances, such as potential clinical compounds. Clinical trials and manufacturing protocols ARE NOT processed in Cayuse. These trials are processed via email submission packages only.

The CU Denver | Anschutz IBC requires a clinical trial submission package including all required documents prior to review consideration at the next IBC meeting. Review the Guidance File for IBC reviewed clinical trials prior to submitting an application. The IBC Clinical Trial Application should be completed as part of the application package. The Biosafety Site-Specific SOP is required for the application package as well.

Tools & Resources

Schools & Colleges

CU Denver

CU Anschutz

CU Campuses

Research Committees

Regulatory Compliance

Planned Outage: InfoEd eRA System

Fri, April 24, 5 p.m. (MST) - Mon, April 27, 8 a.m. (MST)

Institutional Biosafety Committee (IBC)

Office of the Vice Chancellor for Research

Planned Outage: InfoEd eRA System

Fri, April 24, 5 p.m. (MST) - Mon, April 27, 8 a.m. (MST)

Institutional Biosafety Committee (IBC)

Responsibilities of the IBC

Biosafety Authorization Forms

Human Clinical Trial and Manufacturing Protocol Application Information

NIH References

Template Language for IBC Protocols

Additional Links

IBC Meeting Minutes

Office of the Vice Chancellor for Research